IMPORTANT: On Sunday, April 22, we send out an email with some important changes to our newsletter service. Please make sure you read this email, or the details on our our newsletter page, as our newsletter service changes will be taking effect on Monday, May 7, 2018. On that date, your current newsletter subscription will end if you have not subscribed under our new plan.
Shares of Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech developing novel pain-management drugs, soared 56.5% during the first half of 2018, according to data from S&P Global Market Intelligence. Two big announcements drove the stock higher: an important new partnership with a leading dialysis service provider and a positive pivotal trial result for the company's lead candidate.
On Sunday, neuroscientist Brenda Milner turns 100, and she plans to celebrate in two ways: the World Cup finals, followed by a party.
“I tipped France from the beginning of the tournament to win, but I must say that Croatia has really impressed me,” she told STAT recently.
In her 100 years of life, our understanding of the nervous system has changed dramatically.
When you go to your doctor's office, sometimes it seems the caregivers spend more time gathering data about you than treating you as a patient.
Electronic medical records are everywhere – annoying to doctors and intrusive to patients.
But now researchers are looking to see if they can plow through the vast amount of data that's gathered in those records, along with insurance billing information, to tease out the bits that could be useful in refining treatments and identifying new uses for drugs.
President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month. But the pharmaceutical giant wasn’t the only drug company seeking to charge more for its products in recent days.In the first 10 days of July, at least ten other drugmakers and biotechnology companies raised prices on at least 20 brand-name medicines, a review of pricing data from Rx Savings Solutions and Bloomberg Intelligence shows.
A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.